About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

INIBO, a Korean botulinum-toxin product in which Huaxi Bio has a strategic stake, received approval from the National Medical Products Administration; Huaxi is the exclusive mainland China partner. The arrangement combines strategic investment and ma

2026-10-30

INIBO, a Korean botulinum-toxin product in which Huaxi Bio has a strategic stake, received approval from the National Medical Products Administration; Huaxi is the exclusive mainland China partner. The arrangement combines strategic investment and market cooperation to broaden Huaxi’s medical-aesthetics product coverage, diversify its business mix and support long-term development. This extends a prior exclusive-agency collaboration with Korea’s INIBIO for a facial-rejuvenation injection.

Other News
2026-10-29

As of October 27, the Token Spending Price Index was $0.92 per million tokens, a decrease of approximately 4.2% from $0.96 a week earlier. This index briefly rebounded to $0.95 on October 25 before falling back again, averaging $0.92 on October 26 an

As of October 27, the Token Spending Price Index was $0.92 per million tokens, a decrease of approximately 4.2% from $0.96 a week earlier. This index briefly rebounded to $0.95 on October 25 before falling back again, averaging $0.92 on October 26 and 27, indicating the short-term rebound failed to hold. Currently, the price is approximately 55.5% lower than the high of $2.0651 reached on May 28, and remains at a low level.
2026-10-30

Intel (INTC.O) CEO: We are willing to mass-produce any CPU for our customers.

Intel (INTC.O) CEO: We are willing to mass-produce any CPU for our customers.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.